Compass PathwaysCMPS stock surged Monday after President Donald Trump signed an executive order to ease the approval journey for psychedelic drugs. The order has two key elements. It provides a speedy ...

Last weekend, President Donald Trump signed an executive order aimed at accelerating the review of psychedelic therapies for mental health conditions. At a high level, the order does three things. It ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will ...

Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...

President Donald Trump is trying to fast-track research into psychedelics as treatments, creating new opportunities and risks.

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive ...

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered ...

Trump’s executive order could shorten regulatory timelines and bring institutional capital into psychedelics faster than expected. While most peers are early-stage, Compass Pathways is already in ...